Evidence map›Paper›PMID 27888683›Full record

ArticlePsychiatry research2017

Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort.

Anja P Husa, Jani Moilanen, Graham K Murray, Riikka Marttila, Marianne Haapea, Irina Rannikko, Jennifer H Barnett, Peter B Jones, Matti Isohanni, Anne M Remes and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychiatry research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anja P HusaDepartment of Psychiatry, Research Unit of Clinical Neuroscience, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland; Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Psychiatry, Oulu University Hospital, P.O. Box 26, 90029 OYS, Oulu, Finland. Electronic address: anja.husa@student.oulu.fi.
Jani MoilanenDepartment of Psychiatry, Research Unit of Clinical Neuroscience, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland; Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Psychiatry, Oulu University Hospital, P.O. Box 26, 90029 OYS, Oulu, Finland. Electronic address: jani.m.moilanen@student.oulu.fi.
Graham K MurrayDepartment of Psychiatry, University of Cambridge, Box 189 Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom; Behavioural and Clinical Neuroscience Institute, University of Cambridge, Herchel Smith Building, Forvie Site, Cambridge Biomedical Campus, Cambridge CB2 0SZ, United Kingdom. Electronic address: gm285@cam.ac.uk.
Riikka MarttilaMedical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland; Center for Life Course Health Research, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland. Electronic address: riikka.e.marttila@gmail.com.
Marianne HaapeaMedical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland; Center for Life Course Health Research, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland; Department of Diagnostic Radiology, Oulu University Hospital, P.O. Box 50, 90029 OYS, Finland. Electronic address: marianne.haapea@oulu.fi.
Irina RannikkoDepartment of Psychiatry, Research Unit of Clinical Neuroscience, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland; Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. Electronic address: irina@rannikko.org.
Jennifer H BarnettDepartment of Psychiatry, University of Cambridge, Box 189 Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom; Cambridge Cognition Ltd., Tunbridge Court, Bottisham, Cambridge, United Kingdom. Electronic address: jhb32@cam.ac.uk.
Peter B JonesDepartment of Psychiatry, University of Cambridge, Herchel Smith Building, Cambridge CB2 0SZ, United Kingdom. Electronic address: pbj21@cam.ac.uk.
Matti IsohanniMedical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Psychiatry, Oulu University Hospital, P.O. Box 26, 90029 OYS, Oulu, Finland; Center for Life Course Health Research, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland. Electronic address: matti.isohanni@oulu.fi.
Anne M RemesInstitute of Clinical Medicine - Neurology, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland; Department of Neurology, Kuopio University Hospital, Kuopio, Finland. Electronic address: anne.remes@uef.fi.
Hannu KoponenUniversity of Helsinki and Helsinki University Hospital - Psychiatry, P.O. Box 22, 00014 Helsinki, Finland. Electronic address: hannu.j.koponen@hus.fi.
Jouko MiettunenMedical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland; Center for Life Course Health Research, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland. Electronic address: jouko.miettunen@oulu.fi.
Erika JääskeläinenDepartment of Psychiatry, Research Unit of Clinical Neuroscience, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland; Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland; Center for Life Course Health Research, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland; Oulu Occupational Health, Hallituskatu 36 B, 90100 Oulu, Finland. Electronic address: erika.jaaskelainen@oulu.fi.

Funding

Medical Research Council G0701911
6 · The paper itself

Abstract

This naturalistic study analysed the association between cumulative lifetime antipsychotic dose and cognition in schizophrenia after an average of 16.5 years of illness. Sixty participants with schizophrenia and 191 controls from the Northern Finland Birth Cohort 1966 were assessed at age 43 years with a neurocognitive test battery. Cumulative lifetime antipsychotic dose-years were collected from medical records and interviews. The association between antipsychotic dose-years and a cognitive composite score based on principal component analysis was analysed using linear regression. Higher lifetime antipsychotic dose-years were significantly associated with poorer cognitive composite score, when adjusted for gender, onset age and lifetime hospital treatment days. The effects of typical and atypical antipsychotics did not differ. This is the first report of an association between cumulative lifetime antipsychotic dose and global cognition in midlife schizophrenia. Based on these data, higher lifetime antipsychotic dose-years may be associated with poorer cognitive performance at age 43 years. Potential biases related to the naturalistic design may partly explain the results; nonetheless, it is possible that large antipsychotic doses harm cognition in schizophrenia in the long-term.

Indexed as

Schizophrenic PsychologyAdultAge FactorsAntipsychotic AgentsCognitionCohort StudiesDrug Administration ScheduleFemaleFinlandHumansMaleNeuropsychological TestsSchizophreniaTime FactorsAntipsychotic AgentsAdverse effectCognitionCross-sectionalPsychosisTreatment

Identifiers

PMID27888683
PMCPMC5241225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.